Header Logo

Connection

David Williams to Schistosomiasis

This is a "connection" page, showing publications David Williams has written about Schistosomiasis.
Connection Strength

1.671
  1. Characterization of Lead Compounds Targeting the Selenoprotein Thioredoxin Glutathione Reductase for Treatment of Schistosomiasis. ACS Infect Dis. 2020 03 13; 6(3):393-405.
    View in: PubMed
    Score: 0.690
  2. The redox biology of schistosome parasites and applications for drug development. Curr Pharm Des. 2012; 18(24):3595-611.
    View in: PubMed
    Score: 0.395
  3. Murine immune responses to a novel schistosome egg antigen, SmEP25. Int J Parasitol. 2005 Jul; 35(8):875-82.
    View in: PubMed
    Score: 0.251
  4. Non-covalent inhibitors of thioredoxin glutathione reductase with schistosomicidal activity in vivo. Nat Commun. 2023 06 22; 14(1):3737.
    View in: PubMed
    Score: 0.218
  5. Structure mechanism insights and the role of nitric oxide donation guide the development of oxadiazole-2-oxides as therapeutic agents against schistosomiasis. J Med Chem. 2009 Oct 22; 52(20):6474-83.
    View in: PubMed
    Score: 0.085
  6. High-throughput screening against thioredoxin glutathione reductase identifies novel inhibitors with potential therapeutic value for schistosomiasis. Infect Dis Poverty. 2015 Aug 31; 4:40.
    View in: PubMed
    Score: 0.032
Connection Strength

The connection strength for concepts is the sum of the scores for each matching publication.

Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.